Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials
Publication date May 2017
Publisher Current Partnering
Number of pages 700+ (including appendices)
Report edition 2
Product code CP2110
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in vaccine and adjuvant partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines

 

This report contains a comprehensive listing of all vaccine partnering deals announced since January 2010, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

 

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

 

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

 

One of the key highlights of the report is that over 1,000 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

 

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field.

 

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it.

                                                  

Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

 

Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials includes:

 

  • Trends in vaccine dealmaking in the biopharma industry since 2010
  • Analysis of vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life vaccine deals
  • Access to over 1,000 vaccine deal documents
  • The leading vaccine deals by value since 2010
  • Most active vaccine dealmakers since 2010
  • The leading vaccine partnering resources

 

In Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type

 

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 880 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise vaccine rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Vaccine Partnering Terms and Agreements 2010-2017: Deal trends, players and financials provides the reader with the following key benefits:

 

  • In-depth understanding of vaccine and adjuvant deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of vaccine agreements with numerous real life case studies
  • Comprehensive access to over 1,000 actual vaccine deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual vaccine contracts enter into by leading bio pharma companies
  • Identify leading vaccine deals by value since 2010
  • Identify the most active vaccine dealmakers since 2010
  • Insight into the terms included in a vaccine agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Vaccines dealmaking


2.1. Introduction
2.2. Vaccines partnering over the years
2.3. Most active Vaccines dealmakers
2.4. Vaccines partnering by deal type
2.5. Vaccines partnering by therapy area
2.6. Deal terms for Vaccines partnering
2.6.1 Vaccines partnering headline values
2.6.2 Vaccines deal upfront payments
2.6.3 Vaccines deal milestone payments
2.6.4 Vaccines royalty rates

 

Chapter 3 – Leading Vaccines deals

 

3.1. Introduction
3.2. Top Vaccines deals by value

 

Chapter 4 – Most active Vaccines dealmakers

 

4.1. Introduction
4.2. Most active Vaccines dealmakers
4.3. Most active Vaccines partnering company profiles

 

Chapter 5 – Vaccines contracts dealmaking directory

 

5.1. Introduction
5.2. Vaccines contracts dealmaking directory

 

Chapter 6 – Vaccines dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Vaccines deals by company A-Z

 

Appendix 2 – Vaccines deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Vaccines deals by deal type

 

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Vaccines deals by therapy area

 

Anaesthetics
Cardiovascular
Central Nervous System
Dental
Gastrointestinal
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

 

Figure 1: Vaccines partnering since 2010
Figure 2: Active Vaccines dealmaking activity since 2010
Figure 3: Vaccines partnering by deal type since 2010
Figure 4: Vaccines partnering by disease type since 2010
Figure 5: Vaccines deals with a headline value
Figure 6: Vaccines deals with an upfront value
Figure 7: Vaccines deals with a milestone value
Figure 8: Vaccines deals with a royalty rate value
Figure 9: Top Vaccines deals by value since 2010
Figure 10: Most active Vaccines dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

You may also be interested in the following product(s)

Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials

Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials

$3,495.00
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

$2,995.00
   

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2017 Wildwood Ventures Ltd.